98%
921
2 minutes
20
Background: Patients with synchronous metastatic nasopharyngeal carcinoma (smNPC) exhibit significant heterogeneity, and clinical prognostic models suitable for this cohort remain limited. We aimed to develop a prognostic prediction tool to facilitate personalised prognostic assessments and inform treatment decisions for these patients.
Methods: This retrospective multicentre study enrolled 556 patients with smNPC. The training cohort comprised 386 patients from Guangxi Medical University Cancer Hospital, while the external validation cohort comprised 170 patients from Wuzhou Red Cross Hospital and Xiangtan Central Hospital. We applied the Cox proportional hazards model to determine factors associated with overall survival (OS). A nomogram prognostic model was developed to predict OS based on the identified prognostic factors. The model's predictive performance was evaluated for discrimination and calibration, and patients were stratified based on their calculated prognostic risk scores. Kaplan-Meier survival curves were employed to assess prognostic differences across the stratified groups.
Results: Multivariate analysis identified that M classification, primary tumour radiotherapy, and immunotherapy were significantly associated with OS. A prognostic nomogram integrating these variables exhibited good discrimination (C-index: 0.743) and calibration, which was validated in an external validation cohort. Patients stratified by the model-derived risk scores into high- and low-risk groups showed a significant difference in survival disparity.
Conclusions: We established a nomogram prognostic model that effectively facilitated individualised prognostic prediction and risk stratification in patients with smNPC, thereby assisting clinicians in treatment decision-making.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927208 | PMC |
http://dx.doi.org/10.1186/s13014-025-02602-1 | DOI Listing |
Clin Orthop Relat Res
September 2025
Leni & Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Peripheral nerve injury commonly results in pain and long-term disability for patients. Recovery after in-continuity stretch or crush injury remains inherently unpredictable. However, surgical intervention yields the most favorable outcomes when performed shortly after injury.
View Article and Find Full Text PDFInt J Surg
September 2025
Department of Radiology, Sichuan Provincial People's Hospital East Sichuan Hospital&Dazhou First People's Hospital, Dazhou, China.
Genes Genomics
September 2025
Department of Clinical Laboratory, The First Affiliated Hospital of Guilin Medical University, Le Qun Road 15, Guilin, 541001, Guangxi, China.
Background: Lung cancer (LC) is the leading cause of cancer-related deaths globally. Genetic variants in mismatch repair (MMR) genes, such as MutS homolog 2 (MSH2), MutS homolog 6 (MSH6) and MutL homolog 1 (MLH1), may influence individual susceptibility and clinical outcomes in LC.
Objective: This study investigated the associations of genetic polymorphisms in MSH2, MSH6, and MLH1 with susceptibility and survival outcomes in lung cancer patients in the Guangxi Zhuang population.
Med Oncol
September 2025
Division of Hematology and Blood Bank, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients.
View Article and Find Full Text PDFCurr Med Sci
September 2025
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: To develop a novel prognostic scoring system for severe cytokine release syndrome (CRS) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy, aiming to optimize risk mitigation strategies and improve clinical management.
Methods: This single-center retrospective cohort study included 125 B-ALL patients who received anti-CD19 CAR-T-cell therapy from January 2017 to October 2023. These cases were selected from a cohort of over 500 treated patients on the basis of the availability of comprehensive baseline data, documented CRS grading, and at least 3 months of follow-up.